Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methyldopa (Racemic). The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | BLM | P54132 | 4/20 | 1.00 |
| ▸ | HPGD | P15428 | 4/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 1.00 |
| ▸ | APEX1 | P27695 | 3/20 | 1.00 |
| ▸ | RECQL | P46063 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 2/20 | 1.00 |
| ▸ | FYN | P06241 | 2/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyldopa SCHEMBL1172822 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10TDP1MAPTBLM | |
| Methyldopa SCHEMBL29352376 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10TDP1MAPTBLM | |
| Methyldopa SCHEMBL30176814 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10TDP1MAPTBLM | |
| Methyldopa SCHEMBL1321546 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10TDP1MAPTBLM | |
| Methyldopa SCHEMBL34003 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10TDP1MAPTBLM | |
| Methyldopa (Racemic) SCHEMBL5929436 | 0.98 | KDM4E (0.97) | KDM4EHSD17B10TDP1MAPTBLM | |
| Methyldopa (Racemic) SCHEMBL259452 | 0.98 | KDM4E (0.97) | KDM4EHSD17B10TDP1MAPTBLM | |
| Methyldopa SCHEMBL5370162 | 0.98 | KDM4E (0.97) | KDM4EHSD17B10TDP1MAPTBLM | |
| Methyldopa (Racemic) SCHEMBL29013197 | 0.98 | KDM4E (0.97) | KDM4EHSD17B10TDP1MAPTBLM | |
| Methyldopa SCHEMBL11452341 | 0.98 | KDM4E (0.97) | KDM4EHSD17B10TDP1MAPTBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2938 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122080903-A | Foam profile control agent and preparation method and application thereof | — | 2026-05-26 | — | — | CN | claimed |
| US-20250051976-A1 | FIBER COMPOSITE STRUCTURE AND MANUFACTURING METHOD THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2025-02-13 | — | — | US | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| US-20240225978-A1 | METHODS AND COMPOSITIONS FOR PHARMACOLOGICAL TREATMENT OF BLEPHAROPTOSIS | Bokman, Christine Lynn (US) | 2024-07-11 | — | — | US | claimed |
| WO-2024099420-A1 | DRUG-CONTAINING DEVICES, SUPRACHOROIDAL SPACE IMPLANTS, AND ADAPTERS FOR INJECTION | BEIJING SIGHTNOVO MEDICAL TECHNOLOGY CO., LTD (CN) | 2024-05-16 | — | — | WO | claimed |
| EP-3737676-B1 | ACETAL COMPOUNDS AND THERAPEUTIC USES THEREOF | LIGAND PHARM INC (US) | 2024-03-06 | — | — | EP | claimed |
| EP-4297868-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | Hoth Therapeutics, Inc. (US) | 2024-01-03 | — | — | EP | claimed |
| CN-114539948-B | Aqueous binder and application thereof | 远景动力技术(江苏)有限公司 | 2023-12-05 | — | — | CN | claimed |
| EP-4267123-A1 | METHODS FOR PRODUCING D-?-METHYLDOPA | ImmunoMolecular Therapeutics, Inc. (US) | 2023-11-01 | — | — | EP | claimed |
| CN-115286635-B | Synthesis method of chiral pyrazolone compound | 河南师范大学 | 2023-10-24 | — | — | CN | claimed |
| EP-0139983-A1 | Crystalline salts of L or (S)-3-(3,4-dihydroxyphenyl)-2-methylalanine esters and process | MERCK & CO. INC. (US) | 1985-05-08 | — | — | EP | claimed |
| EP-0098475-A2 | Pharmaceutical composition, its manufacture and use | Beiersdorf Aktiengesellschaft (DE) | 1984-01-18 | — | — | EP | claimed |
| US-RE31244-E | Antihypertensive pyridylguanidine compounds | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 1983-05-17 | — | — | US | claimed |
| EP-0036145-A1 | An orally administered drug form comprising a polar bioactive agent and an adjuvant | INTERx RESEARCH CORPORATION (US) | 1981-09-23 | — | — | EP | claimed |
| EP-0036138-A2 | Composition of matter for topical application comprising a bio-affecting agent and N,N-diethyl-m-toluamide | MERCK & CO. INC. (US) | 1981-09-23 | — | — | EP | claimed |
| US-4256108-A | Microporous-semipermeable laminated osmotic system | ALZA CORPORATION (US) | 1981-03-17 | — | — | US | claimed |
| US-4238306-A | Electrodialysis process for the separation of non-essential amino acids from derivatives thereof | RESEARCH PRODUCTS REHOVOT LTD. (IL) | 1980-12-09 | — | — | US | claimed |
| US-4230883-A | REACTION OF CORRESPONDING AMINO ACID WITH HCL OR HBR IN THE ABSENCE OF A SOLVENT | MERCK & CO., INC. (US) | 1980-10-28 | — | — | US | claimed |
| US-4075335-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1978-02-21 | — | — | US | claimed |
| US-3998955-A | 2-CARBOXY OR 2-ALKOXYCARBONYL-PYRIDINES | CIBA-GEIGY CORPORATION (US) | 1976-12-21 | — | — | US | claimed |